Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease
Identifieur interne :
001711 ( PascalFrancis/Curation );
précédent :
001710;
suivant :
001712
Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease
Auteurs : O. Rascol [
France] ;
N. Fabre [
France] ;
O. Blin ;
J. Poulik [
France] ;
U. Sabatini [
France] ;
J.-M. Senard [
France] ;
M. Ane [
France] ;
J.-L. Montastruc [
France] ;
A. RascolSource :
-
Movement disorders [ 0885-3185 ] ; 1994.
RBID : Pascal:94-0662072
Descripteurs français
English descriptors
pA |
A01 | 01 | 1 | | @0 0885-3185 |
---|
A03 | | 1 | | @0 Mov. disord. |
---|
A05 | | | | @2 9 |
---|
A06 | | | | @2 4 |
---|
A08 | 01 | 1 | ENG | @1 Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease |
---|
A11 | 01 | 1 | | @1 RASCOL (O.) |
---|
A11 | 02 | 1 | | @1 FABRE (N.) |
---|
A11 | 03 | 1 | | @1 BLIN (O.) |
---|
A11 | 04 | 1 | | @1 POULIK (J.) |
---|
A11 | 05 | 1 | | @1 SABATINI (U.) |
---|
A11 | 06 | 1 | | @1 SENARD (J.-M.) |
---|
A11 | 07 | 1 | | @1 ANE (M.) |
---|
A11 | 08 | 1 | | @1 MONTASTRUC (J.-L.) |
---|
A11 | 09 | 1 | | @1 RASCOL (A.) |
---|
A14 | 01 | | | @1 INSERM Univ. hosp., dep. clinical pharmacology @2 31073 Toulouse @3 FRA @Z 1 aut. @Z 6 aut. @Z 8 aut. |
---|
A14 | 02 | | | @1 INSERM Univ. hosp., dep. neurology @2 31073 Toulouse @3 FRA @Z 2 aut. @Z 4 aut. @Z 5 aut. @Z 8 aut. |
---|
A14 | 03 | | | @1 Univ. hosp., dep. clinical pharmacology @2 Marseille @3 FRA @Z 7 aut. |
---|
A20 | | | | @1 437-440 |
---|
A21 | | | | @1 1994 |
---|
A23 | 01 | | | @0 ENG |
---|
A43 | 01 | | | @1 INIST @2 20953 @5 354000040679490090 |
---|
A44 | | | | @0 0000 |
---|
A45 | | | | @0 31 ref. |
---|
A47 | 01 | 1 | | @0 94-0662072 |
---|
A60 | | | | @1 P |
---|
A61 | | | | @0 A |
---|
A64 | 01 | 1 | | @0 Movement disorders |
---|
A66 | 01 | | | @0 USA |
---|
C02 | 01 | X | | @0 002B02B06 |
---|
C03 | 01 | X | FRE | @0 Parkinson maladie @2 NM @5 01 |
---|
C03 | 01 | X | ENG | @0 Parkinson disease @2 NM @5 01 |
---|
C03 | 01 | X | SPA | @0 Parkinson enfermedad @2 NM @5 01 |
---|
C03 | 02 | X | FRE | @0 Naltrexone @2 NK @2 FR @5 04 |
---|
C03 | 03 | X | FRE | @0 Antagoniste @5 05 |
---|
C03 | 03 | X | ENG | @0 Antagonist @5 05 |
---|
C03 | 03 | X | SPA | @0 Antagonista @5 05 |
---|
C03 | 04 | X | FRE | @0 Opiacés @5 06 |
---|
C03 | 04 | X | ENG | @0 Opiates @5 06 |
---|
C03 | 04 | X | SPA | @0 Opiados @5 06 |
---|
C03 | 05 | X | FRE | @0 Antiparkinsonien @5 16 |
---|
C03 | 05 | X | ENG | @0 Antiparkinson agent @5 16 |
---|
C03 | 05 | X | SPA | @0 Antiparkinsoniano @5 16 |
---|
C03 | 06 | X | FRE | @0 Traitement @5 17 |
---|
C03 | 06 | X | ENG | @0 Treatment @5 17 |
---|
C03 | 06 | X | GER | @0 Aufbereiten @5 17 |
---|
C03 | 06 | X | SPA | @0 Tratamiento @5 17 |
---|
C03 | 07 | X | FRE | @0 Homme @5 20 |
---|
C03 | 07 | X | ENG | @0 Human @5 20 |
---|
C03 | 07 | X | SPA | @0 Hombre @5 20 |
---|
C03 | 08 | X | FRE | @0 Etude double insu @5 23 |
---|
C03 | 08 | X | ENG | @0 Double blind study @5 23 |
---|
C03 | 08 | X | SPA | @0 Estudio doble ciego @5 23 |
---|
C03 | 09 | X | FRE | @0 Morphinane dérivé @2 FR @5 27 |
---|
C03 | 09 | X | ENG | @0 Morphinan derivatives @2 FR @5 27 |
---|
C07 | 01 | X | FRE | @0 Système nerveux pathologie @5 37 |
---|
C07 | 01 | X | ENG | @0 Nervous system diseases @5 37 |
---|
C07 | 01 | X | SPA | @0 Sistema nervioso patología @5 37 |
---|
C07 | 02 | X | FRE | @0 Système nerveux central pathologie @5 38 |
---|
C07 | 02 | X | ENG | @0 Central nervous system disease @5 38 |
---|
C07 | 02 | X | SPA | @0 Sistema nervosio central patología @5 38 |
---|
C07 | 03 | X | FRE | @0 Encéphale pathologie @5 39 |
---|
C07 | 03 | X | ENG | @0 Cerebral disorder @5 39 |
---|
C07 | 03 | X | SPA | @0 Encéfalo patología @5 39 |
---|
C07 | 04 | X | FRE | @0 Extrapyramidal syndrome @5 40 |
---|
C07 | 04 | X | ENG | @0 Extrapyramidal syndrome @5 40 |
---|
C07 | 04 | X | SPA | @0 Extrapiramidal síndrome @5 40 |
---|
C07 | 05 | X | FRE | @0 Maladie dégénérative @5 41 |
---|
C07 | 05 | X | ENG | @0 Degenerative disease @5 41 |
---|
C07 | 05 | X | SPA | @0 Enfermedad degenerativa @5 41 |
---|
C07 | 06 | X | FRE | @0 Chimiothérapie @5 45 |
---|
C07 | 06 | X | ENG | @0 Chemotherapy @5 45 |
---|
C07 | 06 | X | SPA | @0 Quimioterapia @5 45 |
---|
N21 | | | | @1 321 |
---|
|
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001941
Links to Exploration step
Pascal:94-0662072
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease</title>
<author><name sortKey="Rascol, O" sort="Rascol, O" uniqKey="Rascol O" first="O." last="Rascol">O. Rascol</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>INSERM Univ. hosp., dep. clinical pharmacology</s1>
<s2>31073 Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Fabre, N" sort="Fabre, N" uniqKey="Fabre N" first="N." last="Fabre">N. Fabre</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>INSERM Univ. hosp., dep. neurology</s1>
<s2>31073 Toulouse</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Blin, O" sort="Blin, O" uniqKey="Blin O" first="O." last="Blin">O. Blin</name>
</author>
<author><name sortKey="Poulik, J" sort="Poulik, J" uniqKey="Poulik J" first="J." last="Poulik">J. Poulik</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>INSERM Univ. hosp., dep. neurology</s1>
<s2>31073 Toulouse</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Sabatini, U" sort="Sabatini, U" uniqKey="Sabatini U" first="U." last="Sabatini">U. Sabatini</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>INSERM Univ. hosp., dep. neurology</s1>
<s2>31073 Toulouse</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Senard, J M" sort="Senard, J M" uniqKey="Senard J" first="J.-M." last="Senard">J.-M. Senard</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>INSERM Univ. hosp., dep. clinical pharmacology</s1>
<s2>31073 Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Ane, M" sort="Ane, M" uniqKey="Ane M" first="M." last="Ane">M. Ane</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Univ. hosp., dep. clinical pharmacology</s1>
<s2>Marseille</s2>
<s3>FRA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Montastruc, J L" sort="Montastruc, J L" uniqKey="Montastruc J" first="J.-L." last="Montastruc">J.-L. Montastruc</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>INSERM Univ. hosp., dep. clinical pharmacology</s1>
<s2>31073 Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>INSERM Univ. hosp., dep. neurology</s1>
<s2>31073 Toulouse</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Rascol, A" sort="Rascol, A" uniqKey="Rascol A" first="A." last="Rascol">A. Rascol</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">94-0662072</idno>
<date when="1994">1994</date>
<idno type="stanalyst">PASCAL 94-0662072 INIST</idno>
<idno type="RBID">Pascal:94-0662072</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001941</idno>
<idno type="wicri:Area/PascalFrancis/Curation">001711</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease</title>
<author><name sortKey="Rascol, O" sort="Rascol, O" uniqKey="Rascol O" first="O." last="Rascol">O. Rascol</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>INSERM Univ. hosp., dep. clinical pharmacology</s1>
<s2>31073 Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Fabre, N" sort="Fabre, N" uniqKey="Fabre N" first="N." last="Fabre">N. Fabre</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>INSERM Univ. hosp., dep. neurology</s1>
<s2>31073 Toulouse</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Blin, O" sort="Blin, O" uniqKey="Blin O" first="O." last="Blin">O. Blin</name>
</author>
<author><name sortKey="Poulik, J" sort="Poulik, J" uniqKey="Poulik J" first="J." last="Poulik">J. Poulik</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>INSERM Univ. hosp., dep. neurology</s1>
<s2>31073 Toulouse</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Sabatini, U" sort="Sabatini, U" uniqKey="Sabatini U" first="U." last="Sabatini">U. Sabatini</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>INSERM Univ. hosp., dep. neurology</s1>
<s2>31073 Toulouse</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Senard, J M" sort="Senard, J M" uniqKey="Senard J" first="J.-M." last="Senard">J.-M. Senard</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>INSERM Univ. hosp., dep. clinical pharmacology</s1>
<s2>31073 Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Ane, M" sort="Ane, M" uniqKey="Ane M" first="M." last="Ane">M. Ane</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Univ. hosp., dep. clinical pharmacology</s1>
<s2>Marseille</s2>
<s3>FRA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Montastruc, J L" sort="Montastruc, J L" uniqKey="Montastruc J" first="J.-L." last="Montastruc">J.-L. Montastruc</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>INSERM Univ. hosp., dep. clinical pharmacology</s1>
<s2>31073 Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>INSERM Univ. hosp., dep. neurology</s1>
<s2>31073 Toulouse</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Rascol, A" sort="Rascol, A" uniqKey="Rascol A" first="A." last="Rascol">A. Rascol</name>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="1994">1994</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antagonist</term>
<term>Antiparkinson agent</term>
<term>Double blind study</term>
<term>Human</term>
<term>Morphinan derivatives</term>
<term>Opiates</term>
<term>Parkinson disease</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Parkinson maladie</term>
<term>Naltrexone</term>
<term>Antagoniste</term>
<term>Opiacés</term>
<term>Antiparkinsonien</term>
<term>Traitement</term>
<term>Homme</term>
<term>Etude double insu</term>
<term>Morphinane dérivé</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA08 i1="01" i2="1" l="ENG"><s1>Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>RASCOL (O.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>FABRE (N.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>BLIN (O.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>POULIK (J.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>SABATINI (U.)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>SENARD (J.-M.)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>ANE (M.)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>MONTASTRUC (J.-L.)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>RASCOL (A.)</s1>
</fA11>
<fA14 i1="01"><s1>INSERM Univ. hosp., dep. clinical pharmacology</s1>
<s2>31073 Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>INSERM Univ. hosp., dep. neurology</s1>
<s2>31073 Toulouse</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Univ. hosp., dep. clinical pharmacology</s1>
<s2>Marseille</s2>
<s3>FRA</s3>
<sZ>7 aut.</sZ>
</fA14>
<fA20><s1>437-440</s1>
</fA20>
<fA21><s1>1994</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000040679490090</s5>
</fA43>
<fA44><s0>0000</s0>
</fA44>
<fA45><s0>31 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>94-0662072</s0>
</fA47>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC02 i1="01" i2="X"><s0>002B02B06</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Naltrexone</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Antagoniste</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Antagonist</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Antagonista</s0>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Opiacés</s0>
<s5>06</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Opiates</s0>
<s5>06</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Opiados</s0>
<s5>06</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Antiparkinsonien</s0>
<s5>16</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Antiparkinson agent</s0>
<s5>16</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Antiparkinsoniano</s0>
<s5>16</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Traitement</s0>
<s5>17</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Treatment</s0>
<s5>17</s5>
</fC03>
<fC03 i1="06" i2="X" l="GER"><s0>Aufbereiten</s0>
<s5>17</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>17</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Homme</s0>
<s5>20</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Human</s0>
<s5>20</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Hombre</s0>
<s5>20</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Etude double insu</s0>
<s5>23</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Double blind study</s0>
<s5>23</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Estudio doble ciego</s0>
<s5>23</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Morphinane dérivé</s0>
<s2>FR</s2>
<s5>27</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Morphinan derivatives</s0>
<s2>FR</s2>
<s5>27</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>41</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Chimiothérapie</s0>
<s5>45</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Chemotherapy</s0>
<s5>45</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Quimioterapia</s0>
<s5>45</s5>
</fC07>
<fN21><s1>321</s1>
</fN21>
</pA>
</standard>
</inist>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PascalFrancis/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001711 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 001711 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= PascalFrancis
|étape= Curation
|type= RBID
|clé= Pascal:94-0662072
|texte= Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease
}}
| This area was generated with Dilib version V0.6.29. Data generation: Wed May 17 19:46:39 2017. Site generation: Mon Mar 4 15:48:15 2024 | ![](Common/icons/LogoDilib.gif) |